Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma
| Autor: | Charles H. Banov, David S. Pearlman, Anjuli Nayak, Judy E. Harrison, Anthony T. Scardella, Gregory Gottschlich, Bernard Silverman, Alan B. Goldsobel, Barry K. Feinstein, Michael S. Lawrence, Bruce F. Friedman, Eric J. Schenkel, William R. Lumry, Allen T. Segal, Robert J. Lapidus, Zev M. Munk, Lucy Shneyer, Kathy L. Lampl, Anthony A. Floreani, Nathan Segall, Paul J. Hannaway, Jonathan Corren, Keith B Nolop |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Pulmonary and Respiratory Medicine
Adult Male Adolescent medicine.drug_class Immunology Anti-Inflammatory Agents Mometasone furoate Placebo Drug Administration Schedule Pulmonary function testing Double-Blind Method medicine Immunology and Allergy Humans Anti-Asthmatic Agents Adverse effect Child Pregnadienediols Asthma Aged Inhalation business.industry Middle Aged medicine.disease Dry-powder inhaler Respiratory Function Tests Treatment Outcome Anesthesia Quality of Life Corticosteroid Female business Mometasone Furoate medicine.drug |
| Zdroj: | Annals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology. 84(4) |
| ISSN: | 1081-1206 |
| Popis: | Background Although inhaled glucocorticoids are recommended for all stages of persistent asthma, compliance with long-term therapy is often poor, leading to significant morbidity and mortality. A simplified, once-daily dosing regimen may foster improved compliance. Objective To compare the efficacy and safety of once-daily (am) administration of mometasone furoate dry powder inhaler (MF DPI) 200 μg and 400 μg with placebo in patients with asthma previously maintained only on short-acting inhaled beta-adrenergic receptor agonists. Methods This was a 12-week, double-blind, placebo-controlled, parallel group study. The mean change from baseline to endpoint (last treatment visit) for FEV 1 was the primary efficacy variable. Results At endpoint, both doses of MF DPI were significantly more effective than placebo ( P ≤ .05) in improving FEV 1 . Based on morning peak expiratory flow rate, once-daily MF DPI 400 μg was more effective than placebo ( P ≤ .001) at endpoint. Both active treatments also demonstrated improvement at endpoint in asthma symptom scores, physician-evaluated response to therapy and use of rescue medication. Although both MF DPI dosages were efficacious, MF DPI 400 μg provided additional improvement in some measures of pulmonary function (eg, morning PEFR) when these agents were administered once daily in the morning. Both doses of MF DPI were well tolerated and treatment-related adverse events occurred at a similar incidence among the three treatment groups. Conclusions The results of this study indicate that once-daily (am) MF DPI provides a convenient and effective treatment option for patients with mild or moderate persistent asthma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|